WO2024059650A2 - New heterodimers for prostate and breast cancer - Google Patents
New heterodimers for prostate and breast cancer Download PDFInfo
- Publication number
- WO2024059650A2 WO2024059650A2 PCT/US2023/074095 US2023074095W WO2024059650A2 WO 2024059650 A2 WO2024059650 A2 WO 2024059650A2 US 2023074095 W US2023074095 W US 2023074095W WO 2024059650 A2 WO2024059650 A2 WO 2024059650A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bbn
- ant
- dupa
- set forth
- formula
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 20
- 206010006187 Breast cancer Diseases 0.000 title description 13
- 208000026310 Breast neoplasm Diseases 0.000 title description 13
- 210000002307 prostate Anatomy 0.000 title description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims abstract description 6
- 239000010949 copper Substances 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 35
- 239000000700 radioactive tracer Substances 0.000 claims description 34
- 239000013256 coordination polymer Substances 0.000 claims description 16
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000008139 complexing agent Substances 0.000 claims description 9
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 8
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 claims description 8
- 229960002684 aminocaproic acid Drugs 0.000 claims description 8
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- SOAPXKSPJAZNGO-WDSKDSINSA-N (2s)-2-[[(1s)-1,3-dicarboxypropyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCC(O)=O SOAPXKSPJAZNGO-WDSKDSINSA-N 0.000 claims description 5
- SOAPXKSPJAZNGO-UHFFFAOYSA-N 2-(1,3-dicarboxypropylcarbamoylamino)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)NC(=O)NC(C(O)=O)CCC(O)=O SOAPXKSPJAZNGO-UHFFFAOYSA-N 0.000 claims description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 5
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 claims description 4
- IYSSKWHJCKNPBJ-UHFFFAOYSA-N CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CCCCCCCCCCCC Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CCCCCCCCCCCC IYSSKWHJCKNPBJ-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 4
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 claims 1
- KOHYJMBRYCXNMR-ICRHTFBISA-N C([C@@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 KOHYJMBRYCXNMR-ICRHTFBISA-N 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract description 21
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract description 20
- 108010073466 Bombesin Receptors Proteins 0.000 abstract description 16
- 102000047481 Gastrin-releasing peptide receptors Human genes 0.000 abstract description 16
- 230000008685 targeting Effects 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 238000001514 detection method Methods 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 238000003384 imaging method Methods 0.000 description 9
- 239000002287 radioligand Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000863 peptide conjugate Substances 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ISEYJGQFXSTPMQ-UHFFFAOYSA-N 2-(phosphonomethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(O)=O ISEYJGQFXSTPMQ-UHFFFAOYSA-N 0.000 description 3
- 108010051479 Bombesin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 239000012217 radiopharmaceutical Substances 0.000 description 3
- 229940121896 radiopharmaceutical Drugs 0.000 description 3
- 230000002799 radiopharmaceutical effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710183768 Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- -1 [ 1,4, 7-triazacyclododecane- 1,4,7- triacetic acid] copper Chemical compound 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- VWYGTDAUKWEPCZ-UHFFFAOYSA-L dichlorocopper;hydrate Chemical compound O.Cl[Cu]Cl VWYGTDAUKWEPCZ-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- UPWPDUACHOATKO-UHFFFAOYSA-K gallium trichloride Chemical compound Cl[Ga](Cl)Cl UPWPDUACHOATKO-UHFFFAOYSA-K 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- AEDROEGYZIARPU-UHFFFAOYSA-K lutetium(iii) chloride Chemical compound Cl[Lu](Cl)Cl AEDROEGYZIARPU-UHFFFAOYSA-K 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
Definitions
- the present disclosure relates generally to the development of radiotracers for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells.
- GRPR Gastrin Releasing Peptide Receptor
- PSMA Prostate Specific Membrane Antigen
- Prostate cancer is the second most leading cause of cancer deaths in men in the U.S. with a projected death total of 34,500 in 2022. While the 5-year survival rate is near 100% for patients presenting with locoregional disease, the death rate increases dramatically (29%) for patients presenting with metastatic disease.
- Most existing therapies, such as chemotherapy and external beam radiation are nonspecific, resulting in collateral damage to healthy tissues and dose-limiting side effects. Therefore, patients with metastatic prostate cancer might respond better to alternative treatments, such as targeted radiotherapy with radiolabeled antibodies, peptides, or small molecules.
- targeted radiotherapy ideally, should also be accompanied by a targeted radioimaging correlate for y scintigraphy, single-photon emission computed tomography (SPECT), or positron emission tomography (PET).
- SPECT single-photon emission computed tomography
- PET positron emission tomography
- PSA Prostate specific antigen
- GRP Gastrin Releasing Peptide
- PSMA prostate specific membrane antigen
- folate hydrolase 1 is present on the neovasculature of most solid tumors, with 95% of all prostate cancers expressing PSMA. Lypmph node and bone metastates are 100% in PSMA expression.
- tumor targeting by radiolabeled urea-based PSMA inhibitors has shown to be clinically useful for molecular imaging.
- the present disclosure provides for novel radiotracers that will be able to reach a larger cohort of patients with prostate cancer. Further, similar to prostate cancer, there are receptors for PSMA and GRPR on breast cancer tissues. Accordingly, these radiotracers may be useful in patients with breast cancer as well.
- the present disclosure is generally directed to radiotracer agents for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells, and use of these agents for detection, staging, and therapy of primary and metastatic prostate cancer (PCa).
- GRPR Gastrin Releasing Peptide Receptor
- PSMA Prostate Specific Membrane Antigen
- PCa primary and metastatic prostate cancer
- the present disclosure relates to a radiotracer compound having the formula of Formula (I):
- DUPA is (2-[3-(l,3-dicarboxypropyl)-ureido]pentanedioic acid);
- X are independently selected from the group consisting of 4-amino-l-carboxymethly- piperidine (CP), 5-ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8- aminooctanoic acid (8-AOC), and paraaminobenzoic acid (AMBA);
- CP 4-amino-l-carboxymethly- piperidine
- 5-Ava 5-ammoniumvaleric acid
- 6-Ahx 6-aminohexanoic acid
- 8-AOC 8- aminooctanoic acid
- AMBA paraaminobenzoic acid
- M is selected from the group consisting of: [ 68 Ga], [ 177 Lu], [ 64 Cu], [ 67 Cu] and [ m IN];
- Y is a metal complexing agent selected from the group consisting of: a dodecane tetraacetic acid (DOTA), [l,4,7-triazacyclododecane-l,4,7-triacetic acid] (NOTA), and cross-bridged
- DOTA dodecane tetraacetic acid
- NOTA [l,4,7-triazacyclododecane-l,4,7-triacetic acid]
- TETA phosphonic acid CB-TE1A1P
- BBN ANT is a BBN antagonist ligand of SEQ ID NO: 1.
- the present disclosure relates to a method for detecting prostate cancer (PCa), the method comprising administering the radiotracer compound of any one of claims 1-18 to a subject suspected to be at risk of PCa.
- FIG. 1 depicts an exemplary structure of a compound of Formula (IA).
- FIG. 2 depicts exemplary structures of compounds of Formula (IB), particularly wherein X is 8-aminooctanoic acid (8-AOC) or 4-amino-l-carboxymethly- piperidine (CP).
- X is 8-aminooctanoic acid (8-AOC) or 4-amino-l-carboxymethly- piperidine (CP).
- FIG. 3 depicts the scheme for the synthesis of Heterodimer peptide-CB cyclam chelator conjugates as prepared and analyzed in the Examples.
- FIGS. 4A-4D depict depicts HPLC (radioactive and UV) profiles of [DUPA- 6-Ahx-([ 64/67 Cu]-NODAGA)-8AOC/CP-BBN ANT] as analyzed in Example 1.
- FIGS. 5A-5D depict concentration of [DUPA-6-Ahx-([ 64/67 Cu]-NODAGA)- 8AOC/CP-BBN ANT] as analyzed in Example 1.
- FIGS. 6A-6F depict stability of [DUPA-6-Ahx-([ 64/67 Cu]-NODAGA)-
- FIGS. 7A & 7B depict in vivo analysis of [DUPA-6-Ahx-([ 64/67 Cu]-
- FIGS. 8A & 8B depict in vivo analysis of (FIG. 8A) [DUPA-6-Ahx-([ 64/67 Cu]- NODAGA)-8AOC -BBN ANT] and (FIG. 8B) [DUPA-6-Ahx-([64/67Cu]-NODAGA)-CP - BBN ANT] in GRPR-expressing tumors.
- FIGS. 9A & 9B depict in vivo analysis of (FIG. 9A) [DUPA-6-Ahx-([ 64/67 Cu]- NODAGA)-8AOC -BBN ANT] and (FIG. 9B) [DUPA-6-Ahx-([64/67Cu]-NODAGA)-CP - BBN ANT] in PSMA-expressing tumors.
- FIGS. 10A-10D depict HPLC (radioactive and UV) profiles of 64 Cu/ nat Cu labeled Heterodimer peptide-CB cyclam conjugates.
- FIGS. 11A-11D depict stability of [DUPA-6-Ahx-([ 64/67 Cu]-NODAGA)- 8AOC/CP-BBN ANT] as analyzed in Example 2.
- FIGS. 12A & 12B depict biodistribution data of (FIG. 12A) 64 Cu-DUPA-6- Ahx-(Lys-TElA)-8AOC-BBN-ANT and (FIG. 12B) 64 Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC- BBN-ANT in Nude mice bearing PC3-PIP tumors as analyzed in Example 2.
- FIGS. 13A-13D depicts biodistribution data of (FIG. 13A) 64 Cu-DUPA-6- Ahx-(Lys-TElA)-8AOC-BBN-ANT and (FIG. 13C) 64 Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC- BBN-ANT and critical ratios of (FIG. 13B) 64 Cu-DUPA-6-Ahx-(Lys-TElA)-8AOC-BBN- ANT and (FIG. 13D) 64 Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC-BBN-ANT in Nude mice bearing PC3 tumors as analyzed in Example 2.
- FIGS. 14A & 14B depict critical ratios of (FIG. 14A) 64 Cu-DUPA-6-Ahx- (Lys-TE1A)-8AOC-BBN-ANT and (FIG. 14B) 64 Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC- BBN-ANT in Nude mice bearing PC3-PIP tumors as analyzed in Example 2.
- the present disclosure relates to theranostic agents for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells, and use of these agents for detection, staging, and therapy of primary and metastatic prostate cancer (PCa).
- GRPR Gastrin Releasing Peptide Receptor
- PSMA Prostate Specific Membrane Antigen
- PCa primary and metastatic prostate cancer
- radiotracer compounds of the present disclosure will have the formula of Formula (I):
- DUPA is (2-[3-(l,3-dicarboxypropyl)-ureido]pentanedioic acid), a small molecule PSMA- targeting probe;
- X are independently selected from the group consisting of 4-amino-l-carboxymethly- piperidine (CP), 5-ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8- aminooctanoic acid (8-AOC), and paraaminobenzoic acid (AMBA);
- CP 4-amino-l-carboxymethly- piperidine
- 5-Ava 5-ammoniumvaleric acid
- 6-Ahx 6-aminohexanoic acid
- 8-AOC 8- aminooctanoic acid
- AMBA paraaminobenzoic acid
- M is selected from the group consisting of: [ 68 Ga], [ 177 Lu], [ 64 Cu], [ 67 Cu], and [ m IN];
- Y is a metal complexing agent selected from the group consisting of: a dodecane tetraacetic acid (DOTA, and particularly, [l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid] (DO3A), [l,4,7-triazacyclododecane-l,4,7-triacetic acid] (NOTA), and particularly its derivative, NODAGA, and cross-bridged TETA phosphonic acid (CB-TE1A1P); and
- DOTA dodecane tetraacetic acid
- DO3A dodecane tetraacetic acid
- NOTA [l,4,7-triazacyclododecane-l,4,7-triacetic acid]
- CB-TE1A1P cross-bridged TETA phosphonic acid
- BBN ANT is a BBN antagonist ligand of SEQ ID NO:1 [D-Phe-Gln-Trp-Ala-Val-Gly-His- Sta-Leu-NFh].
- the theranostic agents include [ 68 Ga], [ 177 Lu] and/or [ in IN] (Table 1), two of which, [ 68 Ga] and [ 177 Lu], are well-validated and clinically used diagnostic and therapeutic radioisotopes.
- [ 68 Ga] is a generator-produced ([ 68 Ge]/[ 68 Ga]) radionuclide with a half-life of 1.13 h. The physical half-life of [ 68 Ga] is sufficiently long enough for radiopharmaceutical preparation, quality control validation, and PET molecular imaging investigations.
- [ 68 Ga] decays 89% through positron emission (maximum energy of 1.899 MeV, average energy of 0.89 MeV).
- [Ga 3+ ] is considered to be a hard metal center, preferentially complexing to hard donor atoms such as oxygen and nitrogen.
- [ 177 Lu] is a rare-earth radionuclide that is produced in moderate specific activity (740 GBq/mg) by direct neutron capture of enriched [ 176 Lu] via the ( 176 Lu(n,y) 177 Lu) nuclear reaction.
- high specific activity, no-carrier-added 177 Lu can also be prepared by an indirect neutron capture nuclear reaction on a 176 Yb target.
- [Ga 3+ ] is also considered to be a hard metal center, preferentially complexing to hard donor atoms such as oxygen and nitrogen.
- Table 1 Description of In Vitro and In Vivo Assays to Validate the Cell-targeting Capacity of Agents in GRPR/PSMA-expressing Cells [0034] Particularly, in these embodiments, the present disclosure is generally directed to the development of a new generation of theranostic, heterobivalent radioligands of formula (IA):
- M [ 68 Ga] or [ 177 Lu] or [ m IN];
- 6-Ahx 6-aminohexanoic acid
- X is selected from the group consisting of 4-amino-l-carboxymethly-piperidine (CP), 5- ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8-aminooctanoic acid (8- AOC), or paraaminobenzoic acid (AMBA), and suitably, is CP;
- BBN ANT BBN antagonist ligand of SEQ ID NO:1;
- DUPA (2-[3-(l,3-dicarboxypropyl)-ureido]pentanedioic acid), a small molecule PSMA- targeting probe
- Suitable radioligands are [DUPA-6-Ahx-([ 68 Ga]Ga-DO3A)-CP-BBN ANT] and [DUPA-6-Ahx-([ 177 Lu]Lu-DO3A)-CP-BBN ANT] radioligands.
- These new radiotracers differ from previously produced radioligands by introduction of 4-amino-l-carboxymethly- piperidine as a new pharmacokinetic modifier as in the structure of clinically-used RM2 (Minamimoto R et al. J Nucl Med 2016; 57:557-62). It has been shown that radioligands of this type have high selectivity and affinity for both GRPR and PSMA (Bandari RP et al., Journal of Medicinal Chemistry, 2021).
- [ 64 Cu] is a cyclotron-produced radionuclide with a sufficiently long-enough half-life (12.7 h) to be considered readily available for radiopharmaceutical preparation, quality control, drug incorporation, circulation, and patient imaging.
- [ 64 Cu] is produced by irradiation of [64Ni] via the ( 64 Ni(p,n) 64 Cu) nuclear reaction.
- [0037] Interest in [ 67 Cu] has recently been reinvigorated by the breakthrough in production of significant quantities of high specific activity radiometal.
- [ 67 Cu] is produced in high specific activity (5.55 GBq/pg) by irradiation of a highly enriched [ 68 Zn] target via the ( 68 Zn(y,p) 67 Cu) nuclear reaction.
- Copper (II) is considered to be a hard metal center, preferentially complexing to hard donor atoms such as oxygen and nitrogen.
- the Anderson research group in collaboration with Wong and Weisman at the University of New Hampshire, developed cross-bridged macrocyclic chelators that have extraordinary kinetic stability with Cu(II) (Boswell CA et al., J Med Chem 2004;47:1465-74). Since that time, they have shown that phosphonate-based moieties also bind stably to Cu(II).
- the cross-bridged chelator with one phosphonate pendant arm for coordination of Cu(II) and one carboxylate arm for conjugation to peptide-based biomolecules allows for complexation of copper radionuclides under mild conditions while maintaining in vivo stability.
- M is selected from the group consisting of [ 68 Ga], [ 64 Cu], and [ 67 Cu];
- X is selected from the group consisting of 4-amino-l-carboxymethly-piperidine (CP), 5- ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8-aminooctanoic acid (8- AOC), or paraaminobenzoic acid (AMBA), and suitably, is CP.
- CP 4-amino-l-carboxymethly-piperidine
- 5-Ava 5- ammoniumvaleric acid
- 6-Ahx 6-aminohexanoic acid
- 8- AOC 8-aminooctanoic acid
- AMBA paraaminobenzoic acid
- the heterobivalent PSMA-/GRPR- targeting agents are conjugated with CBTE1A1P for radiolabeling with [ 64 Cu] and [ 67 Cu] and have the formula of formula (IC):
- M is [ 64 Cu] or [ 67 Cu]
- X is selected from the group consisting of 4-amino-l-carboxymethly-piperidine (CP), 5- ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8-aminooctanoic acid (8- AOC), or paraaminobenzoic acid (AMBA), and suitably, is CP.
- CP 4-amino-l-carboxymethly-piperidine
- 5-Ava 5- ammoniumvaleric acid
- 6-Ahx 6-aminohexanoic acid
- 8- AOC 8-aminooctanoic acid
- AMBA paraaminobenzoic acid
- Suitable new theranostic, heterobivalent radioligands having either formula (IB) or (IC) include: [DUPA-6-Ahx-([ 64/67 Cu]Cu-NOTA)-CP-BBN ANT], [DUPA-6-Ahx- ([ 64/67 CU]CU-NOTA)-8-AOC-BBN ANT], [DUPA-6-Ahx-([ 68 Ga]Ga-NOTA)-CP-BBN ANT], [DUPA-6-Ahx-([ 68 Ga]Ga-NOTA)-8-Aoc-BBN ANT], [DUPA-6-Ahx-([ 64/67 Cu]Cu-CB- TE1A1P)-CP-BBN ANT], and [DUPA-6-Ahx-([ 64/67 Cu]Cu-CB-TElAlP)-8-Aoc-BBN ANT], FIGS.
- the present disclosure is further directed to use of the radiotracer compounds for detecting prostate cancer (PCa) or breast cancer.
- the radiotracer compounds are used for detecting prostate cancer, and particularly, metastatic prostate cancer.
- methods of using the radiotracer compounds include administering the radiotracer compounds described herein to a subject at risk of prostate cancer or breast cancer.
- a subject at risk refers to a subset of individuals who are susceptible to, or at elevated risk of, having pancreatic or breast cancer.
- a subject can be susceptible to, or at elevated risk of, experiencing symptoms due to family history, age, environment, and/or lifestyle. Based on the foregoing, because some of the methods embodiments of the present disclosure are directed to specific subsets or subclasses of identified individuals (that is, the subset or subclass of subjects having or suspected of having pancreatic or breast cancer), not all individuals will fall within the subset or subclass of individuals as described herein for certain diseases, disorders or conditions.
- the term “subject” includes both human subjects and animal subjects. Particularly suitable human subjects include pediatric human subjects, adolescent human subjects and adult human subjects.
- “pediatric human subject” refers to a human subject ranging in age from about 2 years old to about 9 years old.
- “adolescent human subject” refers to a human subject having an age of about 10 years old to about 19 years old.
- adult human subject refers to a human subject having an age of 19 and older.
- “susceptible” and “at risk” refer to having little resistance to a certain disease, disorder or condition, including being genetically predisposed, having a family history of, and/or having symptoms of the disease, disorder or condition.
- PET positron Emission Tomography
- MicroCT and Tl- and diffusion-weighted microMRI images could be used to assist in anatomically correlating regions of physiological accumulation and retention of tracer comopunds determined by PET in order to identify primary or metastatic pancreatic or breast cancer.
- the methods of the present disclosure could further include treating the subject found to have pancreatic or breast cancer.
- “treating” refers to processes involving a slowing, interrupting, arresting, controlling, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease, but does not necessarily involve a total elimination of all disease-related symptoms, conditions, or disorders associated with administration of the therapy.
- Treatments as known in the art of pancreatic or breast cancers e.g., surgery, radiation, chemotherapy or a combination of these) could be administered to the subject.
- heterobivalent radiotracers [DUPA-6-Ahx-([M]-NODAGA)- 8-Aoc-BBN ANT] and [DUPA-6-Ahx-([M]-NODAGA)-CP-BBN ANT] were prepared and analyzed for their potential for usage as a single agent with the true matched-pair 64 Cu/ 67 Cu isotopes for therapeutic and diagnostic use and positron emitting 68 Ga diagnostic isotope.
- GRPR/PSMA targeting ligands [DUPA-6-Ahx-([DO3A)-CP-BBN ANT], [DUPA-6-Ahx-([DO3A)-8-Aoc-BBN ANT], [DUPA-6-Ahx-(NODAGA)-8-Aoc-BBN ANT], and [DUPA-6-Ahx-(NODAGA)-CP-BBN ANT] (FIGS. 1 & 2) were purchased from EZBiolab (Carmel, IN, USA).
- [DUPA-6-Ahx-(CB-TElA/TElP)-8-Aoc-BBN ANT] and [DUPA-6-Ahx-(CB-TElA/TElP)-CP-BBN ANT] were prepared and characterized by liquid electrospray ionization-mass spectrometry (ESI-MS), and used without further purification.
- Natural metals Lutetium(III) Chloride, Gallium(III) Chloride, and Copper(II) Chloride hydrate were purchased from Acros Organics and Sigma Aldrich.
- Blocking agents Bombesin 1-14 and 2-(Phosphonomethyl)pentanedioic acid were purchased from Sigma- Aldrich Chemical Company (St.
- PC-3 human prostate carcinoma cell lines were purchased from American Type Tissue Culture Center (ATCC, Rockland, MD) and the PC3-PIP cell lines received from Professor Martin Pomper (John Hopkins University). The cells were maintained in 45% RPMI 1640, 45% Ham’s F-12, and 10% heat-inactivated Fetal Bovine Serum (FBS).
- [DUPA-6-Ahx-([DO3A)-CP-BBN ANT] [DUPA-6-Ahx-([DO3A)-8-Aoc- BBN ANT], [DUPA-6-Ahx-(NODAGA)-8-Aoc-BBN ANT], [DUPA-6-Ahx-(NODAGA)- CP-BBN ANT], [DUPA-6-Ahx-(CB-TElA/TElP)-8-Aoc-BBN ANT], and [DUPA-6-Ahx- (CB-TE1A/TE1P)-CP-BBN ANT] were metalated on the macroscopic level by addition of 1.5 mol of the chloride salts of either nat Cu/ nat Ga/ nat Lu to 1 mol of the heterodimer (100 pL 0.4 M NH4OAC, 300pL 0.05M HC1 pH 4.0) with heating (80°, 45 min). Metalated peptides were characterized by addition of
- Aoc-BBN ANT [DUPA-6-Ahx-(NODAGA)-8-Aoc-BBN ANT], [DUPA-6-Ahx- (NODAGA)-CP-BBN ANT], [DUPA-6-Ahx-(CB-TElA/TElP)-8-Aoc-BBN ANT], and [DUPA-6-Ahx-(CB-TElA/TElP)-CP-BBN ANT] were radiolabeled by addition of 500 mCi of either 177 LuCh, 68 GaCh, or 64/67 CuCh to 1 nmol of peptide (100 pL of 0.4 M NEUOAc) with heating at 80° for 45 minutes.
- PBS phosphate buffered saline
- HS human serum
- RP-HPLC analyses were determined by incubation of the radioligand of interest in 500 pL of PBS at room temperature.
- 500 pL of human serum was incubated with the radioligand at 37°C.
- 500 pL of acetonitrile was added to denature the protein before placing in a centrifuge for 5 mins at 7000 rpm to form a protein pellet. The supernatant was removed from the pellet and each of the fractions were counted in a dose calibrator.
- Each radiotracer was also evaluated for stability via RP-HPLC (see FIGS. 6A-6F).
- purified radiotracer compound 10 pCi, 0.37 MBq, 43 Ci/pmol
- mice For animals with tumor blocking, mice were injected with either 100 pg of commercially available Bombesin (1-14) or 2- (Phosphonomethyl)-pentanedioic acid (PMPA) in isotonic saline 15 mins prior to the injection of the radiolabeled compound. The mice were euthanized at different time points and the tissues and organs were weighed and counted on a Perkin Elmer Wizard 3 automatic gamma counter and the percent injected dose (%ID) and percent injected dose per gram (%ID/g) in each organ or tissue calculated (see FIGS. 7-9).
- %ID percent injected dose
- %ID/g percent injected dose per gram
- MicroPET/SPECT/CT imaging of PC-3 and PC-PIP xenografted CB- 17 SCID mice were conducted at 4- and 24-hour time points post I.V. administration of ⁇ 300 pCi of radiotracer into each mouse.
- 100 mg of BBN(1-14) peptide or 2- PMPA was administered 15 mins prior to injection of the radiotracer compound in both tumors.
- Mice were anesthetized with 2.5% of isoflurane at induction and 2% during imaging for maintenance. The mice were kept warm using a heated water bath on the imaging bed. Data was conducted using a Bruker Albira SI Micor-PET/CT scanner and reconstructed using Vivaquant software. Upon completion of the study, the anesthetized mice were humanely sacrificed by cervical dislocation.
- CB-TE1A1P was synthesized as known in the art.
- the heterodimer peptide conjugation to the two chelators was carried out using the identical procedure. Briefly, CB- TE2A or CB-TE1A1P (10 pmol) and 4 equivalents of DIPEA (7.5 pL) were mixed in DMF (1 mL) and stirred at room temperature for 15 min. To the stirred solution, sulfo-NHS (20 pmol, 4.3 mg) and EDC (10 pmol, 1.9 mg) were added, and the reaction mixture was stirred at room temperature for 4 h.
- mice were injected with purified radiotracer compound ( ⁇ 10 pCi, 0.37 MBq, 43 Ci/pmol) in 150 pL of isotonic saline via the tail vein.
- radiotracer compound ⁇ 10 pCi, 0.37 MBq, 43 Ci/pmol
- mice were injected with either 100 pg of commercially available Bombesin (1-14) or 2-(Phosphonomethyl)-pentanedioic acid (PMPA) in isotonic saline 15 mins prior to the injection of the radiolabeled compound.
- PMPA 2-(Phosphonomethyl)-pentanedioic acid
- mice were euthanized at different time points and the tissues and organs were weighed and counted on a Perkin Elmer Wizard 3 automatic gamma counter and the percent injected dose (%ID) and percent injected dose per gram (%ID/g) in each organ or tissue calculated. Results are shown in FIGS. 12-14.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Theranostic agents for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells, and use of these agents for detection, staging, and therapy of primary and metastatic prostate cancer (PCa) are disclosed.
Description
NEW HETERODIMERS FOR PROSTATE AND BREAST CANCER
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63/375,589 filed on September 14, 2022, which is hereby incorporated by reference in its entirety.
STATEMENT OF GOVERNMENT SUPPORT
[0002] This invention was made with government support under 1I01BX003392 awarded by the U.S. Department of Veterans' Affairs and U01 HL152410 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.
INCORPORATION OF SEQUENCE LISTING
[0003] A paper copy of the Sequence Listing and a computer readable form of the Sequence Listing containing the file named "22UMC036PCT", which is 1899 bytes in size (as measured in MICROSOFT WINDOWS® EXPLORER), are provided herein and are herein incorporated by reference. This Sequence Listing consists of SEQ ID No: 1.
BACKGROUND OF THE DISCLOSURE
[0004] The present disclosure relates generally to the development of radiotracers for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells.
[0005] Prostate cancer is the second most leading cause of cancer deaths in men in the U.S. with a projected death total of 34,500 in 2022. While the 5-year survival rate is near 100% for patients presenting with locoregional disease, the death rate increases dramatically (29%) for patients presenting with metastatic disease.
[0006] Most existing therapies, such as chemotherapy and external beam radiation, are nonspecific, resulting in collateral damage to healthy tissues and dose-limiting side effects. Therefore, patients with metastatic prostate cancer might respond better to alternative treatments, such as targeted radiotherapy with radiolabeled antibodies, peptides, or small molecules. However, targeted radiotherapy, ideally, should also be accompanied by a targeted radioimaging correlate for y scintigraphy, single-photon emission computed tomography (SPECT), or positron emission tomography (PET).
[0007] Prostate specific antigen (PSA) is the most common biomarker tool used clinically for early disease detection with relatively high precision. However, in a number of cases, the PSA determination results in false positive outcomes leading to ambiguity in clinical decision making. With the evolution of receptor-based targeting, there has been a resurgence in development of molecular markers, which has led to high end detection of the disease at various stages of tumor growth enabling effective clinical management of the disease.
[0008] ft has been reported that Gastrin Releasing Peptide (GRP) receptor subtype 2 is overexpressed on several types of human cancer cells with an expression rate of approximately 84% on primary prostate tumors; lymph node and bone metastases are 52.9% and 85.7%, respectively, ft has been shown previously that peptide-based agonist/antagonist radioligands are clinically useful for molecular imagining and therapy.
[0009] Additionally, prostate specific membrane antigen (PSMA), also known as folate hydrolase 1 is present on the neovasculature of most solid tumors, with 95% of all prostate cancers expressing PSMA. Lypmph node and bone metastates are 100% in PSMA expression. Previously, tumor targeting by radiolabeled urea-based PSMA inhibitors has shown to be clinically useful for molecular imaging.
[0010] Based on the foregoing, there is a significant need for a single agent for detection, staging and therapy. The present disclosure provides for novel radiotracers that will be able to reach a larger cohort of patients with prostate cancer. Further, similar to prostate cancer, there are receptors for PSMA and GRPR on breast cancer tissues. Accordingly, these radiotracers may be useful in patients with breast cancer as well.
BRIEF DESCRIPTION OF THE DISCLOSURE
[0011] The present disclosure is generally directed to radiotracer agents for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells, and use of these agents for detection, staging, and therapy of primary and metastatic prostate cancer (PCa). As there are receptors for PSMA and GRPR on breast cancer tissues. Accordingly, these radiotracers may be useful in patients with breast cancer as well
[0012] In one aspect, the present disclosure relates to a radiotracer compound having the formula of Formula (I):
DUPA-X-M-Y-X-BBN ANT Formula (I) wherein:
DUPA is (2-[3-(l,3-dicarboxypropyl)-ureido]pentanedioic acid);
X are independently selected from the group consisting of 4-amino-l-carboxymethly- piperidine (CP), 5-ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8- aminooctanoic acid (8-AOC), and paraaminobenzoic acid (AMBA);
M is selected from the group consisting of: [68Ga], [177Lu], [64Cu], [67Cu] and [mIN];
Y is a metal complexing agent selected from the group consisting of: a dodecane tetraacetic acid (DOTA), [l,4,7-triazacyclododecane-l,4,7-triacetic acid] (NOTA), and cross-bridged
TETA phosphonic acid (CB-TE1A1P); and
BBN ANT is a BBN antagonist ligand of SEQ ID NO: 1.
[0013] In another aspect, the present disclosure relates to a method for detecting prostate cancer (PCa), the method comprising administering the radiotracer compound of any one of claims 1-18 to a subject suspected to be at risk of PCa.
BRIEF DESCRIPTON OF THE DRAWINGS
[0014] The disclosure will be better understood, and features, aspects and advantages other than those set forth above will become apparent when consideration is given to the following detailed description thereof. Such detailed description makes reference to the following drawings, wherein:
[0015] FIG. 1 depicts an exemplary structure of a compound of Formula (IA).
[0016] FIG. 2 depicts exemplary structures of compounds of Formula (IB), particularly wherein X is 8-aminooctanoic acid (8-AOC) or 4-amino-l-carboxymethly- piperidine (CP).
[0017] FIG. 3 depicts the scheme for the synthesis of Heterodimer peptide-CB cyclam chelator conjugates as prepared and analyzed in the Examples.
[0018] FIGS. 4A-4D depict depicts HPLC (radioactive and UV) profiles of [DUPA- 6-Ahx-([64/67Cu]-NODAGA)-8AOC/CP-BBN ANT] as analyzed in Example 1.
[0019] FIGS. 5A-5D depict concentration of [DUPA-6-Ahx-([64/67Cu]-NODAGA)- 8AOC/CP-BBN ANT] as analyzed in Example 1.
[0020] FIGS. 6A-6F depict stability of [DUPA-6-Ahx-([64/67Cu]-NODAGA)-
8AOC/CP-BBN ANT] as analyzed in Example 1.
[0021] FIGS. 7A & 7B depict in vivo analysis of [DUPA-6-Ahx-([64/67Cu]-
NODAGA)-8AOC/CP-BBN ANT] in the GRPR-expressing tumors, PC3 (FIG. 7A) and PC3
PIP (FIG. 7B).
[0022] FIGS. 8A & 8B depict in vivo analysis of (FIG. 8A) [DUPA-6-Ahx-([64/67Cu]- NODAGA)-8AOC -BBN ANT] and (FIG. 8B) [DUPA-6-Ahx-([64/67Cu]-NODAGA)-CP - BBN ANT] in GRPR-expressing tumors.
[0023] FIGS. 9A & 9B depict in vivo analysis of (FIG. 9A) [DUPA-6-Ahx-([64/67Cu]- NODAGA)-8AOC -BBN ANT] and (FIG. 9B) [DUPA-6-Ahx-([64/67Cu]-NODAGA)-CP - BBN ANT] in PSMA-expressing tumors.
[0024] FIGS. 10A-10D depict HPLC (radioactive and UV) profiles of 64Cu/natCu labeled Heterodimer peptide-CB cyclam conjugates.
[0025] FIGS. 11A-11D depict stability of [DUPA-6-Ahx-([64/67Cu]-NODAGA)- 8AOC/CP-BBN ANT] as analyzed in Example 2.
[0026] FIGS. 12A & 12B depict biodistribution data of (FIG. 12A) 64Cu-DUPA-6- Ahx-(Lys-TElA)-8AOC-BBN-ANT and (FIG. 12B) 64Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC- BBN-ANT in Nude mice bearing PC3-PIP tumors as analyzed in Example 2.
[0027] FIGS. 13A-13D depicts biodistribution data of (FIG. 13A) 64Cu-DUPA-6- Ahx-(Lys-TElA)-8AOC-BBN-ANT and (FIG. 13C) 64Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC- BBN-ANT and critical ratios of (FIG. 13B) 64Cu-DUPA-6-Ahx-(Lys-TElA)-8AOC-BBN- ANT and (FIG. 13D) 64Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC-BBN-ANT in Nude mice bearing PC3 tumors as analyzed in Example 2.
[0028] FIGS. 14A & 14B depict critical ratios of (FIG. 14A) 64Cu-DUPA-6-Ahx- (Lys-TE1A)-8AOC-BBN-ANT and (FIG. 14B) 64Cu-DUPA-6-Ahx-(Lys-TElP)-8AOC- BBN-ANT in Nude mice bearing PC3-PIP tumors as analyzed in Example 2.
DETAILED DESCRIPTION
[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure belongs.
[0030] The present disclosure relates to theranostic agents for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells, and use of these agents for detection, staging, and therapy of primary and metastatic prostate cancer (PCa). These new radiotracers would allow the nuclear medicine physician to capture all stages of the disease, a requirement which could be severely limited by monovalent GRPR- or PSMA-targeting ligands, where one or the other molecular biomarkers is expressed in low numbers or not at all.
[0031] Generally, the radiotracer compounds of the present disclosure will have the formula of Formula (I):
DUPA-X-M-Y-X-BBN ANT Formula (I) wherein:
DUPA is (2-[3-(l,3-dicarboxypropyl)-ureido]pentanedioic acid), a small molecule PSMA- targeting probe;
X are independently selected from the group consisting of 4-amino-l-carboxymethly- piperidine (CP), 5-ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8- aminooctanoic acid (8-AOC), and paraaminobenzoic acid (AMBA);
M is selected from the group consisting of: [68Ga], [177Lu], [64Cu], [67Cu], and [mIN];
Y is a metal complexing agent selected from the group consisting of: a dodecane tetraacetic acid (DOTA, and particularly, [l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid] (DO3A), [l,4,7-triazacyclododecane-l,4,7-triacetic acid] (NOTA), and particularly its derivative, NODAGA, and cross-bridged TETA phosphonic acid (CB-TE1A1P); and
BBN ANT is a BBN antagonist ligand of SEQ ID NO:1 [D-Phe-Gln-Trp-Ala-Val-Gly-His- Sta-Leu-NFh].
[0032] In some suitable embodiments, the theranostic agents include [68Ga], [177Lu] and/or [inIN] (Table 1), two of which, [68Ga] and [177Lu], are well-validated and clinically
used diagnostic and therapeutic radioisotopes. [68Ga] is a generator-produced ([68Ge]/[68Ga]) radionuclide with a half-life of 1.13 h. The physical half-life of [68Ga] is sufficiently long enough for radiopharmaceutical preparation, quality control validation, and PET molecular imaging investigations. [68Ga] decays 89% through positron emission (maximum energy of 1.899 MeV, average energy of 0.89 MeV). [Ga3+] is considered to be a hard metal center, preferentially complexing to hard donor atoms such as oxygen and nitrogen.
[0033] [177Lu] is a rare-earth radionuclide that is produced in moderate specific activity (740 GBq/mg) by direct neutron capture of enriched [176Lu] via the (176Lu(n,y)177Lu) nuclear reaction. [177Lu] has a half-life of 6.71 d, decays by beta emission (Epmax = 0.497 MeV), and emits two SPECT imaging gamma photons (113 keV, 3% and 208 keV, 11%). In addition, high specific activity, no-carrier-added 177Lu can also be prepared by an indirect neutron capture nuclear reaction on a 176Yb target. Like [Ga3+], [Lu3+] is also considered to be a hard metal center, preferentially complexing to hard donor atoms such as oxygen and nitrogen.
Table 1 : Description of In Vitro and In Vivo Assays to Validate the Cell-targeting Capacity of Agents in GRPR/PSMA-expressing Cells
[0034] Particularly, in these embodiments, the present disclosure is generally directed to the development of a new generation of theranostic, heterobivalent radioligands of formula (IA):
DUPA-6-Ahx-([M]-DOTA)-X-BBN ANT Formula (IA) wherein
M = [68Ga] or [177Lu] or [mIN];
DOTA = dodecane tetraacetic acid metal complexing agent, particularly (DO3A) = [1,4,7,10- tetraazacyclododecane- 1 ,4,7, 10-tetraacetic acid] ;
6-Ahx = 6-aminohexanoic acid;
X is selected from the group consisting of 4-amino-l-carboxymethly-piperidine (CP), 5- ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8-aminooctanoic acid (8- AOC), or paraaminobenzoic acid (AMBA), and suitably, is CP;
BBN ANT = BBN antagonist ligand of SEQ ID NO:1; and
DUPA = (2-[3-(l,3-dicarboxypropyl)-ureido]pentanedioic acid), a small molecule PSMA- targeting probe
[0035] Suitable radioligands are [DUPA-6-Ahx-([68Ga]Ga-DO3A)-CP-BBN ANT] and [DUPA-6-Ahx-([177Lu]Lu-DO3A)-CP-BBN ANT] radioligands. These new radiotracers differ from previously produced radioligands by introduction of 4-amino-l-carboxymethly- piperidine as a new pharmacokinetic modifier as in the structure of clinically-used RM2 (Minamimoto R et al. J Nucl Med 2016; 57:557-62). It has been shown that radioligands of this type have high selectivity and affinity for both GRPR and PSMA (Bandari RP et al., Journal of Medicinal Chemistry, 2021).
[0036] In other suitable embodiments, copper can be used as the radioisotope. [64Cu] is a cyclotron-produced radionuclide with a sufficiently long-enough half-life (12.7 h) to be considered readily available for radiopharmaceutical preparation, quality control, drug
incorporation, circulation, and patient imaging. [64Cu] is produced by irradiation of [64Ni] via the (64Ni(p,n)64Cu) nuclear reaction. [64Cu]Cu-labelled radiopharmaceuticals are of primary interest due to the ideal nuclear characteristics of [64Cu]: [64Cu] (tl/2=12.7 h; E +max = 0.65 MeV (17.5%); E0“max = 0.57 MeV (38.5%); electron capture (EC) (44.0%)). [0037] Interest in [67Cu] has recently been reinvigorated by the breakthrough in production of significant quantities of high specific activity radiometal. [67Cu] is produced in high specific activity (5.55 GBq/pg) by irradiation of a highly enriched [68Zn] target via the (68Zn(y,p)67Cu) nuclear reaction. [67Cu] has a half-life of 2.58 d, decays by beta emission (E0“max = 0.562 MeV) and emits two SPECT imaging gamma photons (93 keV, 16% and 185 keV, 49%).
[0038] Copper (II) is considered to be a hard metal center, preferentially complexing to hard donor atoms such as oxygen and nitrogen. The Anderson research group, in collaboration with Wong and Weisman at the University of New Hampshire, developed cross-bridged macrocyclic chelators that have extraordinary kinetic stability with Cu(II) (Boswell CA et al., J Med Chem 2004;47:1465-74). Since that time, they have shown that phosphonate-based moieties also bind stably to Cu(II). The cross-bridged chelator with one phosphonate pendant arm for coordination of Cu(II) and one carboxylate arm for conjugation to peptide-based biomolecules (CB-TE1A1P), allows for complexation of copper radionuclides under mild conditions while maintaining in vivo stability.
[0039] In some embodiments, usage of (poly)aminocarboxylate complexing agents based upon NOTA [l,4,7-triazacyclododecane-l,4,7-triacetic acid] to complex [68Ga], [64Cu], and [67Cu] are disclosed. Compounds of these embodiments have the formula of formula (IB):
DUPA-6-Ahx-([M]-NOTA)-X-BBN ANT Formula (IB) wherein
M is selected from the group consisting of [68Ga], [64Cu], and [67Cu]; and
X is selected from the group consisting of 4-amino-l-carboxymethly-piperidine (CP), 5- ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8-aminooctanoic acid (8- AOC), or paraaminobenzoic acid (AMBA), and suitably, is CP.
[0040] In other of the present embodiments, the heterobivalent PSMA-/GRPR- targeting agents are conjugated with CBTE1A1P for radiolabeling with [64Cu] and [67Cu] and have the formula of formula (IC):
DUPA-6-Ahx-([M]-CB-TElAlP)-X-BBN ANT Formula (IC) wherein
M is [64Cu] or [67Cu]; and
X is selected from the group consisting of 4-amino-l-carboxymethly-piperidine (CP), 5- ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8-aminooctanoic acid (8- AOC), or paraaminobenzoic acid (AMBA), and suitably, is CP.
[0041] Suitable new theranostic, heterobivalent radioligands having either formula (IB) or (IC) include: [DUPA-6-Ahx-([64/67Cu]Cu-NOTA)-CP-BBN ANT], [DUPA-6-Ahx- ([64/67CU]CU-NOTA)-8-AOC-BBN ANT], [DUPA-6-Ahx-([68Ga]Ga-NOTA)-CP-BBN ANT], [DUPA-6-Ahx-([68Ga]Ga-NOTA)-8-Aoc-BBN ANT], [DUPA-6-Ahx-([64/67Cu]Cu-CB- TE1A1P)-CP-BBN ANT], and [DUPA-6-Ahx-([64/67Cu]Cu-CB-TElAlP)-8-Aoc-BBN ANT], FIGS. 1-3). In the context of the structural motifs, M = [68Ga], [64Cu], or [67Cu]; 6- Ahx = 6-aminohexanoic acid; 8-Aoc = 8-aminooctanoic acid, CP = 4-amino-l- carboxymethlypiperidine; NOTA (NOTA/NODAGA) = [ 1,4, 7-triazacyclododecane- 1,4,7- triacetic acid] copper complexing agents; CB-TE1A1P = cross-bridged TETA phosphonic acid, a cyclam-based (phosphonate), cross-bridged copper complexing agent; BBN ANT = BBN antagonist ligand [D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NFb] (SEQ ID NO:1), a GRPR-specific peptide targeting probe; and DUPA = (2-[3-(l,3-dicarboxypropyl)-
ureido]pentanedioic acid), a small molecule PSMA-targeting probe. For derivatives containing NOD AGA, the use of [68Ga] radiometal for PET molecular imaging is disclosed.
[0042] The present disclosure is further directed to use of the radiotracer compounds for detecting prostate cancer (PCa) or breast cancer. Suitably, in one particular embodiment, the radiotracer compounds are used for detecting prostate cancer, and particularly, metastatic prostate cancer. Generally, methods of using the radiotracer compounds include administering the radiotracer compounds described herein to a subject at risk of prostate cancer or breast cancer.
[0043] As defined herein, "a subject at risk" refers to a subset of individuals who are susceptible to, or at elevated risk of, having pancreatic or breast cancer. A subject can be susceptible to, or at elevated risk of, experiencing symptoms due to family history, age, environment, and/or lifestyle. Based on the foregoing, because some of the methods embodiments of the present disclosure are directed to specific subsets or subclasses of identified individuals (that is, the subset or subclass of subjects having or suspected of having pancreatic or breast cancer), not all individuals will fall within the subset or subclass of individuals as described herein for certain diseases, disorders or conditions. The term “subject” includes both human subjects and animal subjects. Particularly suitable human subjects include pediatric human subjects, adolescent human subjects and adult human subjects. As used herein, "pediatric human subject" refers to a human subject ranging in age from about 2 years old to about 9 years old. As used herein, "adolescent human subject" refers to a human subject having an age of about 10 years old to about 19 years old. As used herein, "adult human subject" refers to a human subject having an age of 19 and older.
[0044] As used herein, “susceptible” and “at risk” refer to having little resistance to a certain disease, disorder or condition, including being genetically predisposed, having a family history of, and/or having symptoms of the disease, disorder or condition.
[0045] Generally, positron Emission Tomography (PET) could be used to assess the targeting capabilities of the radiotracer compounds in GRPR-/PSMA-expressing tumors. MicroCT and Tl- and diffusion-weighted microMRI images could be used to assist in anatomically correlating regions of physiological accumulation and retention of tracer comopunds determined by PET in order to identify primary or metastatic pancreatic or breast cancer.
[0046] Once detected, the methods of the present disclosure could further include treating the subject found to have pancreatic or breast cancer. As used herein, “treating” (or “treat” or “treatment”) refers to processes involving a slowing, interrupting, arresting, controlling, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease, but does not necessarily involve a total elimination of all disease-related symptoms, conditions, or disorders associated with administration of the therapy. Treatments as known in the art of pancreatic or breast cancers (e.g., surgery, radiation, chemotherapy or a combination of these) could be administered to the subject.
EXAMPLES
EXAMPLE 1
[0047] In this Example, heterobivalent radiotracers [DUPA-6-Ahx-([M]-NODAGA)- 8-Aoc-BBN ANT] and [DUPA-6-Ahx-([M]-NODAGA)-CP-BBN ANT] were prepared and analyzed for their potential for usage as a single agent with the true matched-pair 64Cu/67Cu isotopes for therapeutic and diagnostic use and positron emitting 68Ga diagnostic isotope.
General Materials
[0048] GRPR/PSMA targeting ligands [DUPA-6-Ahx-([DO3A)-CP-BBN ANT], [DUPA-6-Ahx-([DO3A)-8-Aoc-BBN ANT], [DUPA-6-Ahx-(NODAGA)-8-Aoc-BBN ANT], and [DUPA-6-Ahx-(NODAGA)-CP-BBN ANT] (FIGS. 1 & 2) were purchased from EZBiolab (Carmel, IN, USA). [DUPA-6-Ahx-(CB-TElA/TElP)-8-Aoc-BBN ANT] and
[DUPA-6-Ahx-(CB-TElA/TElP)-CP-BBN ANT] (FIG. 3) were prepared and characterized by liquid electrospray ionization-mass spectrometry (ESI-MS), and used without further purification. Natural metals Lutetium(III) Chloride, Gallium(III) Chloride, and Copper(II) Chloride hydrate were purchased from Acros Organics and Sigma Aldrich. Blocking agents Bombesin 1-14 and 2-(Phosphonomethyl)pentanedioic acid were purchased from Sigma- Aldrich Chemical Company (St. Louis, MO, USA) and Tocris Bioscience (Bristol, UK). All other solvents and reagents were purchased from Fisher Scientific (Pittsburgh, PA, USA) or Sigma-Aldrich Chemical Company (St. Louis, MO, USA). The PC-3 human prostate carcinoma cell lines were purchased from American Type Tissue Culture Center (ATCC, Rockland, MD) and the PC3-PIP cell lines received from Professor Martin Pomper (John Hopkins University). The cells were maintained in 45% RPMI 1640, 45% Ham’s F-12, and 10% heat-inactivated Fetal Bovine Serum (FBS). All metallated peptide conjugates were purified via RP-HPLC (reversed phase-high performance liquid chromatography) performed on an SCL-10A Shimadzu system (Kyoto, Japan) with an analytical Phenomenex Jupiter Proteo C-18 column. The HPLC chromatographic profiles of [DUPA-6-Ahx-([DO3A)-CP- BBN ANT], [DUPA-6-Ahx-([DO3A)-8-Aoc-BBN ANT], [DUPA-6-Ahx-(NODAGA)-8- Aoc-BBN ANT], and [DUPA-6-Ahx-(NODAGA)-CP-BBN ANT] are shown in FIGS. 4A- 4D.
Preparation and Characterization of nat Metallated Complexes
[0049] [DUPA-6-Ahx-([DO3A)-CP-BBN ANT], [DUPA-6-Ahx-([DO3A)-8-Aoc- BBN ANT], [DUPA-6-Ahx-(NODAGA)-8-Aoc-BBN ANT], [DUPA-6-Ahx-(NODAGA)- CP-BBN ANT], [DUPA-6-Ahx-(CB-TElA/TElP)-8-Aoc-BBN ANT], and [DUPA-6-Ahx- (CB-TE1A/TE1P)-CP-BBN ANT] were metalated on the macroscopic level by addition of 1.5 mol of the chloride salts of either natCu/natGa/natLu to 1 mol of the heterodimer (100 pL 0.4 M NH4OAC, 300pL 0.05M HC1 pH 4.0) with heating (80°, 45 min). Metalated peptides were characterized by ESI-MS.
Preparation of Radiolabeled Complexes
[0050] [DUPA-6-Ahx-([DO3A)-CP-BBN ANT], [DUPA-6-Ahx-([DO3A)-8-
Aoc-BBN ANT], [DUPA-6-Ahx-(NODAGA)-8-Aoc-BBN ANT], [DUPA-6-Ahx- (NODAGA)-CP-BBN ANT], [DUPA-6-Ahx-(CB-TElA/TElP)-8-Aoc-BBN ANT], and
[DUPA-6-Ahx-(CB-TElA/TElP)-CP-BBN ANT] were radiolabeled by addition of 500 mCi of either 177LuCh, 68GaCh, or 64/67CuCh to 1 nmol of peptide (100 pL of 0.4 M NEUOAc) with heating at 80° for 45 minutes. 50 pL of lOmM DTPA was added to scavenge any unbound metal and radiochemical purity was determined via RP-HPLC. All complexes were radiolabeled in very high radiochemical purity (>95% radiochemical purity) and isolated by C-18 sep-pak prior to all other investigations (see FIGS. 5A-5D).
Stability Investigations of Radiolabeled Complexes
[0051] Stability studies of the radiotracers were completed in phosphate buffered saline (PBS) and human serum (HS) followed by RP-HPLC analyses at different time points. PBS studies were determined by incubation of the radioligand of interest in 500 pL of PBS at room temperature. For serum stability, 500 pL of human serum was incubated with the radioligand at 37°C. After incubation at the selected time points, 500 pL of acetonitrile was added to denature the protein before placing in a centrifuge for 5 mins at 7000 rpm to form a protein pellet. The supernatant was removed from the pellet and each of the fractions were counted in a dose calibrator. Each radiotracer was also evaluated for stability via RP-HPLC (see FIGS. 6A-6F).
In Vivo: Biodistribution and Pharmacokinetics in tumor bearing mice
[0052] In vivo biodistribution studies were completed in male CB-17 SCID mice (n=4, 4-5 weeks old) which were xenografted with either PC3 or PC3-PIP tumors. These studies were conducted in compliance with the standards outlined in the NIH Guide for Care and Use of Laboratory Animals (8th edition) and were approved by the Institutional Animal Care and Use Committee members at the American Association for Laboratory Animal Science (Protocol Number 23101, 08/2021). For biodistribution and pharmacokinetic studies, mice were injected with purified radiotracer compound (=10 pCi, 0.37 MBq, 43 Ci/pmol) in 150 pL of isotonic saline via the tail vein. For animals with tumor blocking, mice were injected with either 100 pg of commercially available Bombesin (1-14) or 2- (Phosphonomethyl)-pentanedioic acid (PMPA) in isotonic saline 15 mins prior to the injection of the radiolabeled compound. The mice were euthanized at different time points and the tissues and organs were weighed and counted on a Perkin Elmer Wizard 3 automatic
gamma counter and the percent injected dose (%ID) and percent injected dose per gram (%ID/g) in each organ or tissue calculated (see FIGS. 7-9).
In Vivo: Molecular Imaging in tumor bearing mice
[0053] MicroPET/SPECT/CT imaging of PC-3 and PC-PIP xenografted CB- 17 SCID mice were conducted at 4- and 24-hour time points post I.V. administration of ~300 pCi of radiotracer into each mouse. For blocking investigations 100 mg of BBN(1-14) peptide or 2- PMPA was administered 15 mins prior to injection of the radiotracer compound in both tumors. Mice were anesthetized with 2.5% of isoflurane at induction and 2% during imaging for maintenance. The mice were kept warm using a heated water bath on the imaging bed. Data was conducted using a Bruker Albira SI Micor-PET/CT scanner and reconstructed using Vivaquant software. Upon completion of the study, the anesthetized mice were humanely sacrificed by cervical dislocation.
EXAMPLE 2
Synthesis
[0054] CB-TE1A1P was synthesized as known in the art. The heterodimer peptide conjugation to the two chelators was carried out using the identical procedure. Briefly, CB- TE2A or CB-TE1A1P (10 pmol) and 4 equivalents of DIPEA (7.5 pL) were mixed in DMF (1 mL) and stirred at room temperature for 15 min. To the stirred solution, sulfo-NHS (20 pmol, 4.3 mg) and EDC (10 pmol, 1.9 mg) were added, and the reaction mixture was stirred at room temperature for 4 h. Thereafter, DMF was removed under reduced pressure and the crude product was washed with acetonitrile (3 x 10 mL) and dichloromethane (3 x 10 mL) respectively to yield the desired activated CB-cyclam NHS-ester. This was then used for the peptide conjugation without any further purification. To a stirred solution of peptide (1 mg, 0.55 pmol) in DMF (0.4 mL), crude activated CB-cyclam NHS ester (TE2A or TE1A1P, 5.0 pmol) was added and the reaction stirred overnight at room temperature. This was then purified using semi-prep HPLC to yield the desired peptide-CB-cyclam TE2A or TE1A1P derivative. The formation of the conjugates (FIG. 3) was characterized by ESI-MS and the yields of the peptide conjugates were calculated by a calibration curve (Concentration vs. Absorbance) of the parent peptide at 254 nm.
D UPA-6-Ahx-(Lys-TElA)-8AOC-BBN-ANT (1)
Yield: 42% (485 pg)
MS (ESI, positive mode): Mass (calculated) 2121.20 m/z (observed) 2121.8; 1061.8 (M/2);
708.2 (M/3); 1415.6 (2M/3)
DUPA-6-Ahx-(Lys-TElP)-8AOC-BBN-ANT )
Yield: 20% (234 pg)
MS (ESI, positive mode): Mass (calculated) 2157.18 m/z (observed) 1079.6(M/2); 720.2 (M/3).
Radiolabeling
[0055] The identical labeling procedure was followed for the two peptide conjugates. 64CuCh (74 MBq; 3-5 pL) was added to the peptide conjugate (1 or 2; 8 nmol) in 0.5 M NIEOAc (pH 5; 80 pL) and heated at 90°C for 45 min. The formation of the complexes (3 and 4) was characterized by HPLC and the radio labeling yields (FIGS. 10A & 10B) observed were >95%. The identity of complexes was established by preparing the natural Cu chelates of the respective peptide conjugates and characterizing them through ESI-MS.
[0056] Briefly, natCuCh (20 nmol) dissolved in water (30 pL) was added to the peptide conjugate (1 or 2; 10 nmol) in 0.5 M NH4OAC (pH 5; 80 pL) and heated at 90°C for 45 min. This was then characterized by UV-HPLC (at 254 nm) and ESI-MS (FIGS. 10C & 10D). natCu-DUPA-6-Ahx-(Lys-TElA)-8AOC-BBN-ANT (5)
MS (ESI, positive mode): Mass (calculated) C102H159CUN24O25 2183.12 m/z (observed) 2184.2; 1092.6 (M/2); 729.0 (M/3); 1456.4 (2M/3) natCu-DUPA-6-Ahx-(Lys-TElP)-8AOC-BBN-ANT (6)
MS (ESI, negative mode): Mass (calculated) C101H159CUN24O26P 2218.09 m/z (observed) 2216.8; 1107.6 (M/2)
Serum stability studies
[0057] To a 450 pL of human serum, 64Cu-complex (3 or 4; 50 pL, 37 MBq) was added and the mixture stirred at 37°C for 1 and 4 h. At the end of each respective time point, the serum mixture (100 pL) was withdrawn, to which ethanol (500 pL) was added to
precipitate out the serum proteins. The ethanolic solution was then centrifuged at 10,000 g to separate out the serum proteins and the supernatant was then analyzed by HPLC for ascertaining the serum stability over time (see FIGS. 11A-1 ID).
Bio-evaluation studies
[0058] Biodistribution studies
[0059] All procedures performed herein were in accordance with the national laws pertaining to the conduct of animal experiments. A solid tumor model in Nude mice bearing PC3-PIP and PC3 was used as described in Example 1. Particularly, mice were injected with purified radiotracer compound (~10 pCi, 0.37 MBq, 43 Ci/pmol) in 150 pL of isotonic saline via the tail vein. For animals with tumor blocking, mice were injected with either 100 pg of commercially available Bombesin (1-14) or 2-(Phosphonomethyl)-pentanedioic acid (PMPA) in isotonic saline 15 mins prior to the injection of the radiolabeled compound. The mice were euthanized at different time points and the tissues and organs were weighed and counted on a Perkin Elmer Wizard 3 automatic gamma counter and the percent injected dose (%ID) and percent injected dose per gram (%ID/g) in each organ or tissue calculated. Results are shown in FIGS. 12-14.
Claims
1. A radiotracer compound having the formula of Formula (I): DUPA-X-M-Y-X-BBN ANT Formula (I) wherein:
DUPA is (2-[3-(l,3-dicarboxypropyl)-ureido]pentanedioic acid);
X are independently selected from the group consisting of 4-amino-l-carboxymethly- piperidine (CP), 5-ammoniumvaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 8- aminooctanoic acid (8-AOC), and paraaminobenzoic acid (AMBA);
M is selected from the group consisting of: [68Ga], [177Lu], [64Cu], [67Cu] and [1UIN];
Y is a metal complexing agent selected from the group consisting of: a dodecane tetraacetic acid (DOTA), [l,4,7-triazacyclododecane-l,4,7-triacetic acid] (NOTA), and cross-bridged TETA phosphonic acid (CB-TE1A1P); and
BBN ANT is a BBN antagonist ligand of SEQ ID NO:1[D-Phe-Gln-Trp-Ala-Val-Gly-His- Sta-Leu-NH2].
2. The radiotracer compound as set forth in claim 1, wherein when M is [68Ga] or [177Lu], Y is DOTA.
3. The radiotracer compound as set forth in claim 1, wherein Y is [1,4,7,10- tetraazacyclododecane-l,4,7,10-tetraacetic acid] (DO3A).
4. The radiotracer compound as set forth in claim 1, wherein when M is selected from the group consisting of [68Ga], [64Cu], and [67Cu], Y is the metal complexing agent NOTA or derivative thereof.
5. The radiotracer compound as set forth in claim 4, wherein Y is NOD AGA.
6. The radiotracer compound as set forth in claim 1, wherein when M is [64Cu] of [67Cu], Y is a cyclam-based (phosphonate), cross-bridged copper complexing agent CB- TE1A1P.
7. The radiotracer compound as set forth in any of claims 1-4, wherein at least one X is 6-Ahx.
8. The radiotracer compound as set forth in any of claims 1-5, wherein both X is 6-Ahx.
9. The radiotracer compound as set forth in claim 1 having the formula of formula IA
DUPA-6-Ahx-([M]- DOTA)-X-BBN ANT Formula (IA) wherein
M is [68Ga], [177Lu] or [i nIN],
10. The radiotracer compound as set forth in claim 9, wherein X is CP.
11. The radiotracer compound as set forth in claim 10 having the formula DUPA- 6-Ahx-([68Ga]- DO3A)-X-BBN ANT.
12. The radiotracer compound as set forth in claim 10 having the formula DUPA- 6-Ahx-([177Lu]- DO3A)-X-BBN ANT.
13. The radiotracer compound as set forth in claim 1 having the formula of formula IB
DUPA-6-Ahx-([M]-NOTA)-X-BBN ANT Formula (IB) wherein
M is selected from the group consisting of [68Ga], [64Cu], and [67Cu].
14. The radiotracer compound as set forth in claim 13, wherein X is CP.
15. The radiotracer compound as set forth in claim 13 having the formula selected from the group consisting of: DUPA-6Ahx-([64Cu]Cu-NOTA)-CP-BBN ANT, DUPA-6Ahx- ([64CU]CU-NOTA)-8-AOC-BBN ANT, DUPA-6Ahx-([67Cu]Cu-NOTA)-CP-BBN ANT, DUPA-6Ahx-([67Cu]Cu-NOTA)-8-Aoc-BBN ANT, DUPA-6Ahx-([68Ga]Ga-NOTA)-CP- BBN ANT, and DUPA-6Ahx-([68Ga]Ga-NOTA)-8-Aoc-BBN ANT.
16. The radiotracer compound as set forth in claim 1 having the formula of formula IC
DUPA-6-Ahx-([M]-CB-TElAlP)-X-BBN ANT Formula (IC) wherein
M is [64Cu] or [67Cu].
17. The radiotracer compound as set forth in claim 16, wherein X is CP.
18. The radiotracer compound as set forth in claim 17 having the formula selected from the group consisting of: DUPA-6Ahx-([64Cu]Cu-CB-TElAlP)-CP-BBN ANT, DUPA- 6Ahx-([64Cu]Cu-CB-TElAlP)-8-Aoc-BBN ANT, DUPA-6Ahx-([67Cu]Cu-CB-TElAlP)- CP-BBN ANT and DUPA-6Ahx-([67Cu]Cu-CB-TElAlP)-8-Aoc-BBN ANT.
19. A method for detecting prostate cancer (PCa), the method comprising administering the radiotracer compound of any one of claims 1-18 to a subject suspected to be at risk of PCa.
20. The method as set forth in claim 19 wherein the prostate cancer is metastatic prostate cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263375589P | 2022-09-14 | 2022-09-14 | |
US63/375,589 | 2022-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024059650A2 true WO2024059650A2 (en) | 2024-03-21 |
WO2024059650A3 WO2024059650A3 (en) | 2024-05-16 |
Family
ID=90275889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/074095 WO2024059650A2 (en) | 2022-09-14 | 2023-09-13 | New heterodimers for prostate and breast cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024059650A2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11660354B2 (en) * | 2016-11-30 | 2023-05-30 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
US11167048B2 (en) * | 2018-12-14 | 2021-11-09 | The Curators Of The University Of Missouri | Dual targeting ligand for cancer diagnosis and treatment |
-
2023
- 2023-09-13 WO PCT/US2023/074095 patent/WO2024059650A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024059650A3 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111491668B (en) | Complex containing PSMA targeting compound connected with lead or thorium radionuclide | |
JP5781026B2 (en) | Ethylenedicysteine (EC) -drug conjugate | |
CN107382890B (en) | Homogenic and xenogenic multivalent inhibitors of Prostate Specific Membrane Antigen (PSMA) and uses thereof | |
JP7500551B2 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents, and pharmaceutical agents for the treatment of psma-expressing cancers - Patents.com | |
IL289989B (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
DK2013221T3 (en) | Compositions and methods for cellular imaging and therapy | |
CN112851637B (en) | PSMA inhibitor, compound, preparation method and application thereof | |
WO2005087275A2 (en) | Metal radiolabeled pet imaging agents | |
JP2008531988A (en) | Radiolabeled gallium complex, its synthesis and use in PET imaging of EGFR expression in malignant tumors | |
CN117209476A (en) | The method comprises the following steps of 99m Tc-labeled radioactive probe for targeting fibroblast activation protein and preparation method and application thereof | |
BRPI0616441B1 (en) | BIOTINE DIAMINO DERIVATIVES AND ITS ASSOCIATES WITH MACROCYCLIC CHELING AGENTS | |
WO2024059650A2 (en) | New heterodimers for prostate and breast cancer | |
EP3711781A1 (en) | Method for preparation of radioisotope chelating polymer nanoparticles for use in diagnostics and treatment | |
Kakkar et al. | Comparative evaluation of glutamate-sensitive radiopharmaceuticals: Technetium-99m–glutamic acid and technetium-99m–diethylenetriaminepentaacetic acid–bis (Glutamate) conjugate for tumor imaging | |
KR101829913B1 (en) | Radioisotope-labelled benzothiazole derivatives and a radiopharmaceutical product comprising the same | |
JP2023522983A (en) | Compositions, kits and methods for diagnosis and treatment of prostate cancer | |
Chhabra et al. | Theragnostic radionuclide pairs for prostate cancer Management: 64Cu/67Cu, can be a budding hot duo. Biomedicines 2022, 10, 2787 | |
Müller et al. | Folate Receptor-Targeted Radionuclide Imaging Agents | |
Ballal et al. | First-In-Human Results On The Biodistribution, Pharmacokinetics, And Dosimetry of [177Lu] Lu-DOTA. SA. FAPi and [177Lu] Lu-DOTAGA.(SA. FAPi) 2 in Patients with Various End-stage Cancers | |
Song et al. | Influence of different 99m Tc cores on the physicochemical and biodistribution behaviours of 99m Tc-labelled complexes of pamidronate dithiocarbamate | |
Heindel et al. | 99mTc 1-aminocyclopentane carboxylic acid: tumor and tissue distribution results on a labeled cytotoxic amino acid | |
Chhabra et al. | Theragnostic Radionuclide Pairs for Prostate Cancer Management | |
Pirovano et al. | Philip J. Blower, Katherine A. Vallis, Raymond M. Reilly | |
JP2024099559A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents, and pharmaceutical agents for the treatment of psma-expressing cancers - Patents.com | |
WO2022136317A1 (en) | Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23866442 Country of ref document: EP Kind code of ref document: A2 |